Survival outcomes following craniotomy for intracranial metastases from an unknown primary

Melissa Gough1 · Molly Nielsen1 · Ian C. Coulter2 · Damian Holliman2

Received: 9 November 2019 / Accepted: 16 April 2020 / Published online: 1 May 2020
© The Author(s) 2020

Abstract

Introduction Management of patients with intracranial metastases from an unknown primary tumor (CUP) varies compared to those with metastases of known primary tumor origin (CKP). The National Institute for Health and Care Excellence (NICE) recognizes the current lack of research to support the management of CUP patients with brain metastases. The primary aim was to compare survival outcomes of CKP and CUP patients undergoing early resection of intracranial metastases to understand the efficacy of surgery for patients with CUP.

Methods A retrospective study was performed, wherein patients were identified using a pathology database. Data was collected from patient notes and trust information services. Surgically managed patients during a 10-year period aged over 18 years, with a histological diagnosis of intracranial metastasis, were included.

Results 298 patients were identified, including 243 (82.0%) CKP patients and 55 (18.0%) CUP patients. Median survival for CKP patients was 9 months (95%CI 7.475–10.525); and 6 months for CUP patients (95%CI 4.263–7.737, p = 0.113). Cox regression analyses suggest absence of other metastases (p = 0.016), age (p = 0.005), and performance status (p = 0.001) were positive prognostic factors for improved survival in cases of CUP. The eventual determination of the primary malignancy did not affect overall survival for CUP patients.

Conclusions There was no significant difference in overall survival between the two groups. Surgical management of patients with CUP brain metastases is an appropriate treatment option. Current diagnostic pathways specifying a thorough search for the primary tumor pre-operatively may not improve patient outcomes.

Keywords Intracranial · Metastasis · Primary · Survival · Unknown

Keypoints

1. NICE guidance does not detail specific management for CUP patients with intracranial metastases.
2. CUP patients with intracranial metastases and those with known primary (CKP) were compared.
3. No significant difference in survival between CUP and CKP groups after surgery for metastases.

Importance of the study

Patients with cancer of an unknown primary (CUP) comprise around 5 – 15% of total cerebral metastases cases, according to a range of sources. NICE guideline, Brain tumours (primary) and brain metastases in adults (NG99, 2018) does not detail specific management guidance for
CUP patients with intracranial metastases. The findings within this study support data elsewhere in the literature that survival outcomes after early resection of intracranial metastases in CUP patients are not significantly different from those in CKP patients. Cox regression analysis within this study revealed that single metastasis, younger age and better Eastern Cooperative Oncology Group (ECOG) performance status are associated with better outcomes in CUP patients undergoing resection of intracranial metastases. We advocate large-scale prospective studies of this patient group to further refine the best treatment options.

**Introduction**

Patients with cancer of an unknown primary (CUP) comprise approximately 5–15% of total cerebral metastases cases [8, 22, 24, 26, 33]. Patients presenting with intracranial metastases from a CUP may not be considered for the same surgical treatment options as those afforded to patients with a known primary cancer (CKP) as knowledge of the primary disease’s prognosis typically facilitates treatment decisions [2]. The approach of reserving surgery until a primary is diagnosed may negate the potential benefits of early surgical management, as is more readily offered to those patients with CKP metastases.

In the United Kingdom in 2010, the National Institute for Health and Care Excellence (NICE) recognized a lack of national research strategy to address the needs of CUP patients with brain metastases [19]. In the NICE Managing metastatic malignant disease of unknown primary origin in adults: diagnosis and management pathways guidance (2018) [21], however, it is recommended that patients and carers be informed that there is no evidence that any treatment offers improved survival nor does surgery improve neurological symptoms in those with multiple brain metastases [21].

NICE has previously noted a lack of adequate epidemiological data regarding these patients [19]. In the cases of solitary metastases from a CKP a referral to the neuro-oncology multi-disciplinary team (MDT) is advised for consideration of radical therapy including surgical excision. There is no specific guidance regarding the management of solitary CUP brain metastases within the updated 2018 NICE guidance (NG99) [20].

We aimed to compare survival of CKP and CUP patients undergoing resection of intracranial metastases to determine whether early neurosurgical intervention is a valid treatment option for patients with CUP.

**Materials and methods**

Surgically managed patients aged over 18 years, with a histological diagnosis of intracranial metastasis during the 10-year study period between January 2008 and April 2018, were identified using our institution’s pathology database. Retrospective data including age, gender, tumor characteristics, mode of adjuvant treatment and Eastern Cooperative Oncology Group Performance Status (ECOG) were collected from patient notes and trust information services using a proforma. The Summary Care Record was interrogated to determine the date of death. Whilst the precise mode of surgical excision was not recorded for this study, surgeons at our centre employ en bloc and piecemeal excision techniques tailored to the particular case. Typically patients receive a post-operative computed tomography (CT) scan to assess for the presence of hematoma and gross residual. An MRI is usually arranged at variable points during follow-up, though this data was not collected and analyzed as part of this study.

Patients were censored from analysis if they were alive at the end of the study period. A diagnosis of CUP was assigned to those patients with no identifiable histological diagnosis regarding primary tumour origin at the time of initial diagnosis of cerebral metastasis.

**Ethical statement**

The study was registered with our institution as a retrospective service evaluation quality assurance study. Whilst a study-specific consent form was not required, all patients undergoing surgery had a valid procedural consent form completed which included permission to collect data for service and quality assurance projects.

**Statistics**

Multivariate analysis was performed using Cox regression analysis, univariate analysis using the Kaplan–Meier (KM) method with comparisons made using the log rank test and independent t-tests were conducted using IBM SPSS Statistics Version 24. Statistical significance was reported if \( p < 0.05 \).

**Results**

Of 326 screened cases, 298 patients met the inclusion criteria (age range 20–83 years; median age 61); this included 267 (82.0%) CKP patients (24 censored (9.0%)) and 59 (18.0%) CUP patients (4 censored (6.8%)). The most common sites
of CKP metastases were the cerebellum (30.3%), frontal lobe (18.0%) and parietal lobe (18.0%). The most common CUP metastasis site was the frontal lobe (30.9%), followed by cerebellum (21.8%). Table 1 illustrates the clinical information of the patient cohort.

### Overall survival

Univariate analysis revealed a median survival for CKP patients of 9 months (95% CI 7.475–10.525); for CUP patients it was 6 months (95% CI 4.263–7.737, Log rank (Mantel–Cox) \( p = 0.113 \)). Eighty-one patients (33.4%) in the CKP group survived for greater than 1 year after metastasis diagnosis, and a single patient (0.4%) survived 5 years. Sixteen patients (29.1%) from the CUP group survived beyond 1 year, whereas no patients survived to 5 years after metastasis diagnosis (Fig. 1).

### Positive predictive factors

Multivariate Cox regression analysis was performed for both CKP and CUP groups containing sets of six and seven potential prognostic variables, respectively (Table 2).

### Adjuvant therapy

Adjuvant therapy comprised radiotherapy, chemotherapy, WBRT, SRS or a paired combination (Table 1). There was no statistically significant difference in survival outcome in relation to whether patients received adjuvant monotherapy or combined therapy (\( p = 0.115 \)). Rather, survival outcomes were improved in both CKP (\( p = 0.031 \)) and CUP (\( p = 0.017 \)) groups simply by the addition of any postoperative adjuvant treatment (chemo- and/or radiotherapy).

### 3-Year recurrence

Median time to recurrence within the CKP group was 7 months (range 0.3–47 months), as opposed to 5 months in the CUP group (range 2–20 months). Patients in the metastasis recurrence group experienced longer survival times than those patients without recurrence. Kaplan–Meier survival analysis of CUP and CKP groups (Fig. 2) demonstrated statistically significant improved survival outcomes among patients with intracranial disease recurrence within both groups CKP (\( p = 0.001 \)) and CUP (\( p = 0.006 \)).

### Survival outcomes stratified by age at metastasis diagnosis

Survival prognosis deteriorated as patient age increased (\( p = 0.003 \)). This observation was confirmed in analyses of

### Table 1 Patient demographics and clinical information

| Total number of patients       | 298 |
|--------------------------------|-----|
| Median age at met diagnosis    |     |
| All                            | 62 years |
| CKP                            | 60 years (range 20–83) |
| CUP                            | 64 years (range 43–80) |
| Gender ratios                  |     |
| All                            | 298  |
| Male                           | 113 (37.9) |
| Female                         | 185 (62.1) |
| CKP                            |     |
| Male                           | 93 (38.3) |
| Female                         | 150 (61.7) |
| CUP                            |     |
| Male                           | 21 (38.2) |
| Female                         | 34 (61.8) |

| Tumor location                  |     |
|---------------------------------|-----|
| CKP                             |     |
| Cerebellum                      | 74 (30.5) |
| Frontal                         | 44 (18.1) |
| Parietal                        | 44 (18.1) |
| Occipital                       | 31 (12.8) |
| Temporal                        | 12 (4.9) |
| Other                           | 38 (15.6) |
| CUP                             |     |
| Frontal                         | 17 (30.9) |
| Cerebellum                      | 12 (21.8) |
| Parietal                        | 5 (9.1) |
| Temporal                        | 4 (7.2) |
| Cerebellopontine angle          | 3 (5.5) |
| Occipital                       | 3 (5.5) |
| Other                           | 11 (20) |

| Primary identified pre-operatively (CKP) |     |
|------------------------------------------|-----|
| Site                                      |     |
| Lung                                     | 77 (31.7) |
| Breast                                   | 64 (26.3) |
| Gastrointestinal                         | 25 (10.3) |
| Melanoma                                 | 16 (6.6) |
| Renal cell                               | 16 (6.6) |
| Ovarian/endometrial/cervical             | 14 (5.8) |
| Prostate                                 | 3 (1.2) |
| Bladder                                  | 2 (0.8) |
| Other                                    | 26 (10.7) |

| Primary not identified pre-operatively (CUP) |     |
|---------------------------------------------|-----|
| Total                                       | 55 (38.2) |
| Identified post-operatively                 | 21 (27.3) |
| Lung                                        | 15 (1.8) |
| Melanoma                                    | 1 (1.8) |
| Renal                                       | 1 (7.2) |
| Other                                       | 4 (61.8) |
| Never identified                            | 34 (38.2) |
both the CKP \( (p = 0.01) \) and CUP \( (p = 0.042) \) patient cohorts (Fig. 3).

**Performance status in CUP patients**

Kaplan–Meier analysis of patients stratified by their performance status revealed that lower Eastern Cooperative Oncology Group (ECOG) performance status significantly correlated with increased survival \( (p = 0.018) \) (Fig. 4).

**Primary site identification in CUP group**

No statistically significant difference in survival outcomes was determined by univariate Kaplan–Meier analysis of CUP patients split into sub-groups according to whether primary site was ever identified \( (p = 0.574) \).

**Single versus multiple metastases**

Both CKP and CUP groups showed preponderance for single cerebral metastasis as opposed to multiple metastases (Table 1). A statistically significant difference was found between CKP patients with single versus multiple metastases \( (p = 0.013) \), wherein those with a single metastasis experienced longer survival. There was no statistically significant difference in survival outcomes between single or multiple metastasis patients within the CUP group \( (p = 0.581) \).

---

**Table 1** (continued)

| Single versus multiple metastases | CKP | CUP |
|----------------------------------|-----|-----|
| Single                           | 198 (81.5) | 42 (76.4) |
| Multiple                         | 39 (16.0) | 11 (20.0) |
| Not recorded                     | 6 (2.5) | 2 (3.6) |

**Post-operative adjuvant therapy**

| CKP                  | Radiotherapy | Chemotherapy | WBRT | Radiotherapy and chemotherapy | WBRT and chemotherapy | SRS | SRS and chemotherapy | None | Not recorded |
|----------------------|--------------|--------------|------|--------------------------------|-----------------------|-----|----------------------|------|--------------|
|                      | 89 (36.6)    | 24 (9.9)     | 14 (5.8) | 41 (16.9)                     | 5 (2.0)               | 3 (1.2) | 1 (0.4)               | 60 (24.7) | 6 (2.5) |
| CUP                  | Radiotherapy | Chemotherapy | WBRT | Radiotherapy and chemotherapy | WBRT and chemotherapy | SRS | SRS and chemotherapy | None | Not recorded |
|                      | 17 (30.9)    | 5 (9.1)      | 12 (21.8) | 3 (5.5)                       | 1 (1.8)               | 13 (23.6) | 4 (7.3)               | 60 (24.7) | 6 (2.5) |

---

**Table 2** CKP and CUP multivariate analysis outputs

| Primary tumour | Exp(B) | Lower | Upper | Sig  |
|----------------|--------|-------|-------|------|
| **CKP**        |        |       |       |      |
| Therapy        | 0.673  | 0.469 | 0.965 | 0.031|
| Single/multiple| 1.652  | 1.060 | 2.576 | 0.027|
| Recurrence     | 1.877  | 1.343 | 2.623 | <0.0001|
| Gender         | 1.036  | 0.746 | 1.439 | 0.833|
| Other mets     | 1.260  | 0.903 | 1.758 | 0.173|
| Age at met diagnosis stratified | 1.177  | 1.004 | 1.381 | 0.044|
| **CUP**        |        |       |       |      |
| Therapy        | 0.177  | 0.042 | 0.735 | 0.017|
| Single/multiple| 0.737  | 0.233 | 2.326 | 0.602|
| Recurrence     | 15.750 | 2.647 | 93.703| 0.002|
| Gender         | 1.930  | 0.505 | 7.366 | 0.336|
| Other mets     | 9.713  | 1.533 | 61.546| 0.016|
| Age at met diagnosis stratified | 8.309  | 1.884 | 36.647| 0.005|
| Performance status stratified | 7.366  | 2.354 | 23.050| 0.001|

\( WBRT \) whole brain radiotherapy, \( SRS \) stereotactic radiosurgery
Presence of extracranial metastases

The most common site of extracranial metastases in the CKP group was lymph nodes (n = 95, 38.9%), followed by lung (n = 62, 25.4%). Forty-eight patients (19.7%) had liver metastases, and 38 (15.6%) had bone metastases. Most patients within the CKP group had other metastases at more than one site. Overall, 163 (66.8%) CKP patients had extra-cranial metastases. Extracranial metastases were found in 26 CUP patients (47.3%). The commonest sites of extra-cranial metastases within the CUP group were lymph nodes and liver (both n = 7, 12.7%).

Discussion

In this retrospective study of 298 patients with brain metastases undergoing surgical excision, there was no significant difference in overall survival between patients with CKP and CUP (9 versus 6 months p = 0.113). This study has not identified the reasons for this, but our findings suggest that (a) metastatic disease and (b) cerebral disease and not necessarily the type of cancer, are the major factors that determine a patient’s length of survival.

The median survival for patients with untreated cerebral metastases is 1–2 months, which may be extended to 6 months with surgery, radiotherapy, and chemotherapy [6].
Riihimaki et al. (2013) analyzed a large series comparing 6,745 patients with metastatic CKP at diagnosis and 2,881 patients with metastatic CUP [29]. They observed that CUP patients had poorer survival than patients with CKP, a finding that was not replicated in our cohort. D’Ambrosio and Agazzi found that there was no significant difference in survival between CUP and CKP patients, suggesting that delayed treatment whilst attempting to locate a primary cancer is inappropriate [4]. Whether the primary is eventually found also did not have a statistically significant impact upon survival outcome, an observation replicated in our study [10]. Positive prognostic indicators examined included age < 65 years and treatment modality used [4]. Polyzoidis et al. reached a similar conclusion that identification of the primary tumor does not affect prognosis and survival. Instead, age, Karnofsky Performance Score (KPS), number of metastases, treatment modality, and extent of extracranial pathology [26] were observed to be more favorable prognostic indicators. Unsurprisingly, provision of any postoperative adjuvant therapy has been shown to improve survival outcomes in this series, which is consistent with other studies in the literature [10].

Median survival among CUP patients with brain metastases has been reported to lie anywhere between 4.8–27 months [1, 11, 15, 34]. CUP patients were found to have longer median overall survival than the group containing all known primary brain metastases patients in the series by Bartelt et al. (4.8 and 3.4 months, respectively; \( p = 0.05 \)) [1]. This wide range of outcomes exemplifies the need to obtain further prospective epidemiological data and analysis including stratification of tumor types and treatment modalities as the management of most primary cancers has become varied and complex. Recently Fureder et al. reported no statistical difference in survival between CUP and CKP patients within 3 months of presentation [16] adding further weight to the hypothesis that there is no difference in survival outcomes between CKP and CUP groups undergoing cranial metastasis excision [1, 7, 15, 23, 26]. Interestingly, one study points out that median survival was significantly higher for treated as opposed to untreated CUP patients (3.6 and 1.1 months, respectively; \( p = 0.0001 \)) [10]. This supports the aforementioned conclusions that surgery should not necessarily be deferred for CUP patients if it is deemed potentially efficacious in the initial management phase.

Previous reports have indicated that surgical intervention contributes towards improved survival in CKP brain metastases patients [3, 13, 31, 32]. These demonstrated that neurosurgery coupled with whole brain radiotherapy (WBRT) leads to favorable survival outcomes when compared to the use of WBRT alone (median survival 9–10 months and 3–6 months, respectively) [14] with a lower recurrence rate in those patients undergoing neurosurgical intervention compared to those who did not (20% and 52%, respectively) [18]. Our study has demonstrated that there was no significant difference in survival outcomes between CKP and CUP patient groups following surgical excision. Further research of larger CUP patient populations, via strategies such as national and international databases, is required to elucidate the factors contributing to this finding. Furthermore, we also observed that adjuvant therapy improved survival for patients with CKP and CUP.

Recently ECOG status (0-1) and absence of extra-cranial metastases were shown to be significantly associated with better survival outcomes after irradiation for CUP brain metastases [28], corroborating results from other studies examining brain metastases from various types of primary tumors and treatment modalities [9, 25, 27]. Most of these studies focus on whole brain radiotherapy (WBRT) with or without neurosurgical resection. Our results concur with those pertaining to the influence of ECOG status on survival for the CUP group. That is, lower ECOG status is statistically associated with improved survival outcomes. Similarly, age consistently inversely correlates with survival parameters [5]. (Fig. 4).

The study is limited in a number of respects. First, precise data pertaining to the mode of surgical excision (en bloc versus piecemeal excision) extent of metastasis resection (gross total versus subtotal) was not recorded. Whilst differentiating the cohort further based on operative techniques and extent of resection would have been ideal this would have led to smaller cohort sizes precluding meaningful statistical comparisons. Similarly, subgroups based on modality of radiation treatment were not created based on the same rationale. Second, this study is based on a small sample size, particularly the CUP cohort.
Such a limitation is not unique to studying this patient population, particularly as neurosurgical treatment for patients with CUP metastases is relatively less common. This is one of the many drawbacks of retrospective studies as typically large sample sizes are necessary to examine for rare outcomes. In addition, our observations are limited by the inherent selection and information biases typical of retrospective studies. The evidence base concerning neurosurgical treatment of CUP metastases is not wide with differing methodologies; therefore, meaningful comparison of epidemiological data from this study with those undergoing similar treatment in other studies may be limited. Nevertheless, our study adds valuable insights to the evolving CUP brain metastases knowledge base.

These data reflect clinically relevant information gleaned during the transition to precision-era medicine, and before its latent effects are fully manifest. The National Research Council defines precision medicine as a means to tailor medical treatment to the individual qualities of individuals and the diseases of which they suffer. Furthermore, it is a means to stratify patients into subgroups differing in their responses to specific diseases as well as their varying responses to treatment [17]. Whilst the laudable goals of precision medicine are slowly becoming more achievable, particularly in oncological practice, in reality the unavailability of effective treatments for the many usually unfortunately means that precision medicine can rarely be practiced. The neurosurgeon and oncologist working today are still forced to act promptly to manage the often-deteriorating patient with CUP with a brain metastasis. In light of this, based on our data and others [12, 30], we would advocate the early consideration of metastasis excision surgery, even when a primary diagnosis remains undetermined.

**Conclusion**

We have measured survival outcomes in a group of patients (CUP) who often present emergently to neurosurgical services. Comparison with a group of CKP patients demonstrates no significant difference in overall survival after neurosurgical intervention, suggesting surgery is a valid treatment option even before an underlying diagnosis is attained. The positive prognostic factors identified add to existing knowledge concerning the optimum treatments for patients with CUP brain metastases. Where prognostic factors indicate a poor survival outcome, less invasive and onerous treatment is perhaps more appropriate. We advocate large-scale prospective studies of this patient group to further refine the best treatment options.

**References**

1. Bartelt S, Lutterbach J (2003) Brain metastases in patients with cancer of unknown primary. J Neurooncol 64:249–253
2. Binder C, Matthes KL, Korol D et al (2018) Cancer of unknown primary-epidemiological trends and relevance of comprehensive genomic profiling. Cancer Med 7:4814–4824
3. Cattell E, Kelly C, Middleton MR (2002) Brain metastases in melanoma: a European perspective. Semin Oncol 29:513–517
4. D’Ambrosio AL, Agazzi S (2007) Prognosis in patients presenting with brain metastasis from an undiagnosed primary tumor. Neurosurg Focus 22:E7
5. Fernandez-Cotarelo MJ, Guerra-Vales JM, Colina F et al (2010) Prognostic factors in cancer of unknown primary site. Tumori 96:111–116
6. Fidler IJ (2015) The biology of brain metastasis: challenges for therapy. Cancer J 21:284–293
7. Furerder LM, Widhalm G, Gatterbauer B et al (2018) Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center. Clin Exp Metastasis 35:727–738
8. Han HH, Jung WHH et al (2016) Optimal treatment decision for brain metastases of unknown primary origin: the role and timing of radiosurgery. Brain Tumor Res Treat 4:107–110
9. Jakhar SL, Kapoor A, Singh D et al (2015) Prognostic factors affecting the survival of patients with brain metastasis treated by whole brain radiotherapy: a regional cancer center experience from North West India. Clin Cancer Investig 4:29–33
10. Kim CS, Hannot MB, Sarma S et al (2018) Survival outcome differences based on treatments used and knowledge of the primary tumour site for patients with cancer of unknown and known primary in Ontario. Curr Oncol 25:307–316
11. Kondziolka D, Patel A, Lunsford LD et al (1999) Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45:427–434
12. Kyritsis AP, Markoula S, Levin VA (2012) A systematic approach to the management of patients with brain metastases of known or unknown primary site. Cancer Chemoth Pharmacol 69:1–13

**Author contributions** Experimental design: DH. Implementation: MN, MG. Data analysis and interpretation: MG. Manuscript draft and revision: MG. Manuscript review: IC, DH.

**Compliance with ethical standards**

**Conflict of interest** No author has any conflict of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
13. Lang FF, Sawaya R (1998) Surgical treatment of metastatic brain tumors. Semin Surg Oncol 14:53–63
14. Le Chevalier T, Smith FP, Caille P et al (1985) Sites of primary malignancies in patients presenting with cerebral metastases. A review of 120 cases. Cancer 56:880–882
15. Maesawa S, Kondziolka D, Thompson TP et al (2000) Brain metastases in patients with no known primary tumor. Cancer 89:1095–1101
16. Mintz AH, Kestle J, Rathbone MP et al (1997) A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78:1470–1476
17. National Research Council (2011) Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. The National Academies Press, Washington, p 142
18. Nguyen LN, Maor MH, Oswald MJ (1998) Brain metastases as the only manifestation of an undetected primary tumor. Cancer 83:2181–2184
19. NICE (2010) Metastatic malignant disease of unknown primary origin in adults: diagnosis and management. [cited 2019 5th March]; Clinical guideline [CG104]
20. NICE (2018) Brain tumours (primary) and brain metastases in adults. [cited 2019 13th February]; NICE guideline [NG99].
21. NICE (2018) Managing metastatic malignant disease of unknown primary origin in adults: diagnosis and management. [cited 2019 19th February]; Clinical guideline [CG104].
22. Nussbaum ES, Djallilian HR, Cho KH et al (1996) Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 78:1781–1788
23. Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500
24. Pavlidis N, Briasoulis E, Hainsworth J et al (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39:1990–2005
25. Pease NJ, Edwards A, Moss LJ (2005) Effectiveness of whole brain radiotherapy in the treatment of brain metastases: a systematic review. Palliat Med 19:288–299
26. Polyzoidis KS, Miliaras G, Pavlidis N (2005) Brain metastasis of unknown primary: a diagnostic and therapeutic dilemma. Cancer Treat Rev 31:247–255
27. Rades D, Dziggel L, Haatanen T et al (2011) Scoring systems to estimate intracerebral control and survival rates of patients irradiated for brain metastases. Int J Radiat Oncol Biol Phys 80:1122–1127
28. Rades D, Dziggel L, Janssen S et al (2018) Predictive factors for local control and survival in patients with cancer of unknown primary (CUP) irradiated for cerebral metastases. Anticancer Res 38:2415–2418
29. Riihimaki M, Thomsen H, Hemminki A et al (2013) Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer. BMC Cancer 13:36
30. Rudà R, Borgognone M, Benech F et al (2001) Brain metastases from unknown primary tumour. J Neurol 248:394–398
31. Salvati M, Frati A, D’Elia A et al (2012) Single brain metastases from melanoma: remarks on a series of 84 patients. Neurosurg Rev 35:211–217 (discussion 217–8)
32. Sawaya R, Ligon BL, Bindal AK et al (1996) Surgical treatment of metastatic brain tumors. J Neurooncol 27:269–277
33. Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34
34. Vosoughi E, Lee JM, Miller JR et al (2018) Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies. BMC Cancer 18:490

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.